EJErika Fernandes Jesus

Erika Fernandes Jesus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erika Fernandes Jesus has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Empagliflozin targets a renal neuro-epithelial-immune axis in heart failure

    by Jennifer Nogueira Coelho, Livia Caires Simonete, Joao Carlos Ribeiro-Silva, Erika Fernandes Jesus, Andreia Boaro, Flavia Leticia Martins, Jose Wilson Correa Do Nascimento, Larissa Ferreira dos Santos, Danubia Silva dos Santos, Ednei L. Antonio, et al.

    Background: Persistent neurohormonal activation is a key driver of maladaptive remodeling and disease progression in heart failure (HF). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) confer robust renoprotective effects in HF; however, the extent to which these benefits involve modulation of renal neurohormonal activity remains unclear. We hypothesized that SGLT2i-mediated renoprotection in HF is associated with attenuation of excessive renal neurohormonal activation. Methods: Male rats with myocardial infarction-induced HF and sham controls were fed standard chow or chow containing empagliflozin (EMPA, 300 mg/kg) for four weeks, followed by assessment of renal inflammatory and neurohormonal markers. Parallel in vitro studies in THP-1 macrophages and HK-2 proximal tubule cells evaluated the direct effects of EMPA on norepinephrine (NE)-dependent tubular inflammatory signaling. Results: HF rats displayed higher renal cortical renin gene expression and angiotensin II concentrations, which remained unaffected by EMPA. Conversely, EMPA normalized the elevated urinary NE excretion and renal cortical NE content observed in HF rats. Given the inflammatory role of sympathetic hyperactivity, we assessed renal macrophage polarization. EMPA-treated HF rats showed reduced expression of pro-inflammatory markers ( Tnf, Ccr2, Nos2, Il-6 ) and increased expression of markers associated with a reparative macrophage profile ( Arg1, Mrc1, CD163 ), supported by higher CD206⁺ macrophages in kidney sections. While EMPA did not directly alter THP-1 macrophage activation in vitro , it significantly reduced NE-induced SGLT2 expression and interleukin-6 (IL-6) release by HK-2 human proximal tubule epithelial cells. Conclusion: These findings support a model in which SGLT2 inhibitors confer renoprotection in HF by suppressing renal sympathetic hyperactivity, independently of the intrarenal renin-angiotensin system, thereby disrupting a maladaptive renal neuro-epithelial-immune axis and promoting a reparative macrophage phenotype. CLINICAL PERSPECTIVE: What’s new?: This study identifies a renal neuro-epithelial-immune axis underlying empagliflozin-mediated renoprotection in heart failure. Empagliflozin reduces renal cortical and urinary norepinephrine levels in heart failure without altering intrarenal renin-angiotensin system activity, revealing a distinct neurohumoral target of SGLT2 inhibition. This sympatholytic effect is associated with a shift in renal macrophages toward a reparative (M2) phenotype, without changes in total macrophage abundance. Empagliflozin blocks norepinephrine-induced SGLT2 upregulation, limiting proximal tubular glucose reabsorption and IL-6 production, and linking sympathetic signaling to renal inflammation. What are the clinical implications?: Our findings provide a mechanistic basis for the additive cardiorenal benefits of SGLT2 inhibitors in heart failure, beyond conventional RAS-directed therapies. Targeting renal sympathetic-driven inflammation may help preserve kidney function and attenuate the progression of cardiorenal syndrome. Suppression of a renal neuroinflammatory pathway may help explain the early and sustained benefits of SGLT2 inhibitors across heart failure phenotypes, including nondiabetic patients.

  • SGLT2 Inhibitors Blunt Kidney Magnesium Wasting in Acute Cisplatin-Induced Hypomagnesemia with Effects on the Thick Ascending Limb and Distal Convoluted Tubule

    by Erika F. Jesus, Weverton M. Luchi, Paulo C. Castro, Flavia L. Martins, Marcos V. Caetano, Vanderlene L. Kung, Antonio C. Seguro, James A. McCormick, Adriana C.C. Girardi

    Key Points: Sodium-glucose cotransporter 2 inhibitors restored magnesium serum levels in cisplatin-treated rats. Empagliflozin reversed cisplatin-induced Na + -K + -Cl − cotransporter 2 inhibition and claudin-16 downregulation in the thick ascending limb. Empagliflozin mitigated distal convoluted tubule area reduction, normalized NaCl cotransporter function, and restored transient receptor potential melastatin 6 expression. Background: Cisplatin, a chemotherapeutic agent, induces kidney magnesium wasting and hypomagnesemia. Recent studies suggest that sodium-glucose cotransporter 2 inhibitors elevate serum magnesium concentration in patients with or without diabetes. We hypothesized that the sodium-glucose cotransporter 2 inhibitor empagliflozin attenuates acute cisplatin-induced hypomagnesemia by acting on the thick ascending limb (TAL) and distal convoluted tubule (DCT), key sites of magnesium reabsorption. Methods: Adult male Wistar rats received weekly treatments of cisplatin (2.5 mg/kg) or saline (vehicle) for 5 weeks. After 3 weeks, rats were randomized to receive empagliflozin (10 mg/kg per day) or water (vehicle) for the next 15 days. Results: Cisplatin-treated rats developed significant hypomagnesemia with increased fractional excretion of magnesium. Empagliflozin treatment reduced fractional excretion of magnesium and restored serum magnesium levels. In the TAL, cisplatin-treated rats had higher Na + -K + -Cl − cotransporter 2 (NKCC2) abundance but lower phosphorylated NKCC2 and claudin-16 levels than empagliflozin-treated cisplatin rats, whose protein levels were similar to controls. By contrast, claudin-19 abundance in the TAL was higher in cisplatin-treated rats than in controls and unaffected by empagliflozin treatment. In the DCT, cisplatin-treated rats displayed reduced abundance of the NaCl cotransporter (NCC), the magnesium channel transient receptor potential melastatin 6, and NCC phosphorylation, all of which were rescued by empagliflozin. Unexpectedly, cisplatin-treated rats exhibited higher mRNA expression and protein abundance of TRPM7 compared with empagliflozin-treated cisplatin rats, whose levels were similar to controls. Diuretic challenge tests with furosemide or hydrochlorothiazide confirmed reduced NKCC2 and NCC activity in cisplatin-treated rats. However, the natriuretic response to furosemide or hydrochlorothiazide did not differ between control and empagliflozin-treated cisplatin rats. Immunohistochemistry suggested that empagliflozin reversed cisplatin-induced DCT remodeling. Conclusions: Empagliflozin reduces kidney magnesium wasting and restores serum magnesium in cisplatin-treated rats, likely through reversing NKCC2 inhibition and claudin-16 downregulation in the TAL while normalizing NCC function and restoring transient receptor potential melastatin 6 expression in the DCT.


  • Open Access

    Impact of Proximal Tubule-Specific Deletion of Dipeptidyl Peptidase 4 on Blood Pressure, Renal Sodium Handling, and NHE3 Phosphorylation

    by Flavia L. Martins, Joao Carlos Ribeiro-Silva, Erika Fernandes de Jesus, Ravi Nistala, Adriana C. C. Girardi

    Dipeptidyl peptidase 4 (DPP4) is a transmembrane serine exopeptidase abundantly expressed in the kidneys, predominantly in the proximal tubule (PT); however, its non-enzymatic functions in this nephron segment remain poorly understood. While DPP4 physically associates with the Na + /H + exchanger isoform 3 (NHE3) and its inhibitors exert natriuretic effects, the DPP4 role in blood pressure (BP) regulation remains controversial. This study investigated the effects of PT-specific Dpp4 deletion ( Dpp4 ΔPT ) and global Dpp4 deletion ( Dpp4 −/− ) on systolic blood pressure (SBP), natriuresis, and NHE3 regulation under baseline and angiotensin II (Ang II)-stimulated conditions in both male and female mice. Global and PT-specific Dpp4 deletion increased diuretic and natriuretic responses to acute saline loading, correlating with enhanced phosphorylation of NHE3 at serine 552 (pS552-NHE3). However, baseline SBP remained unchanged. Ang II stimulation increased DPP4 activity in control mice, with a greater effect in males than in females, reflecting sex-dependent regulation of renal DPP4. In Dpp4 ΔPT mice, residual kidney DPP4 was unresponsive to Ang II, indicating that PT DPP4, rather than DPP4 in other nephron segments, is regulated by Ang II. Ang II administration increased SBP in all groups; however, the pressor response was significantly attenuated in both Dpp4 ΔPT and Dpp4 −/− mice, coinciding with sustained elevated levels of pS552-NHE3. Collectively, these findings demonstrate that PT DPP4 modulates NHE3 activity through mechanisms that prevent the accumulation of pS552-NHE3, exerting an anti-natriuretic effect. In the absence of DPP4, these mechanisms are disrupted, reducing Ang II sensitivity and maintaining high pS552-NHE3 levels, underscoring the role of DPP4 in PT signaling and function.